{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:58:29Z","timestamp":1781179109419,"version":"3.54.1"},"reference-count":16,"publisher":"Scientific Scholar","issue":"03","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To compare the clinical outcomes of neoadjuvant chemotherapy followed by interdigitated brachytherapy versus standard chemoradiation in locally advanced cervical cancer.<\/jats:p>\n                  <jats:p>We enrolled 108 patients with histologically confirmed carcinoma of the cervix, at International Federation of Gynecology and Obstetrics (FIGO) stages IIB to IIIC1. They were then randomized into two groups. The study group received neoadjuvant chemotherapy with paclitaxel 175\u2009mg\/m2 and carboplatin (area under the curve [AUC]: 5) at every 3 weeks, followed by external beam radiotherapy (EBRT) 45 Gy\/20 fractions and concurrent cisplatin with interdigitated high dose rate intracavitary brachytherapy (HDRICBT) 5 Gy\/fraction weekly for a total of four fractions. Patients in the control group received EBRT 50 Gy\/25 fractions and concurrent cisplatin with sequential HDRICBT 7 Gy\/fraction weekly for a total of three fractions.<\/jats:p>\n                  <jats:p>At the end of the study, the results of both groups were compared in terms of response to therapy and acute toxicities. A total of 108 patients were enrolled (54 in each two arms). Ninety-three patients who completed treatment were included in the analysis. The median follow-up duration was 10 months (range: 6\u201318 months). Complete response was observed in 24 (53.3%) and 26 (55.3%) patients, and partial response was in 12 (26.6%) and 12 (25.5%) patients in the study and control groups, respectively. Most of the acute and late toxicities were of grades 1 and 2 and comparable in both groups.<\/jats:p>\n                  <jats:p>In a busy department where resources are limited, neoadjuvant chemotherapy (NACT) followed by EBRT with HDRICBT is an alternative option for current standard concurrent chemoradiation (CCRT) as its tolerance and toxicity are at par with CCRT.<\/jats:p>","DOI":"10.1055\/s-0043-1776014","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T23:08:44Z","timestamp":1755644924000},"page":"404-410","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Chemotherapy Followed by Interdigitated Brachytherapy versus Standard Chemoradiation in Locally Advanced Cervical Cancer"],"prefix":"10.25259","volume":"14","author":[{"given":"B.K.","family":"Shewalkar","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Oncology, Government Medical College and Cancer Hospital Aurangabad, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punita","family":"Pant","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Oncology, Government Medical College and Cancer Hospital Aurangabad, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-2203","authenticated-orcid":false,"given":"Jitendra","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Oncology, Government Medical College and Cancer Hospital Aurangabad, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakanksha","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Oncology, Government Medical College and Cancer Hospital Aurangabad, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"issue":"06","key":"ref1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"F Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s12885-016-2558-9","article-title":"Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand","volume":"16","author":"E Tharavichitkul","year":"2016","journal-title":"BMC Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/IGC.0000000000000663","article-title":"Neoadjuvant chemotherapy followed by chemoradiation in cervical carcinoma: a review","volume":"26","author":"C RAS de Azevedo","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"17","key":"ref4","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/S0959-8049(03)00425-8","article-title":"Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials","volume":"39","author":"Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration","year":"2003","journal-title":"Eur J Cancer"},{"issue":"05","key":"ref5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13224-015-0698-5","article-title":"Pros and cons of adding of neoadjuvant chemotherapy to standard concurrent chemoradiotherapy in cervical cancer: a regional cancer center experience","volume":"66","author":"S Narayan","year":"2016","journal-title":"J Obstet Gynecol India"},{"issue":"33","key":"ref6","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1200\/JCO.19.00674","article-title":"Neoadjuvant chemotherapy with cisplatin and gemcitabine followed by chemoradiation versus chemoradiation for locally advanced cervical cancer: a randomized phase II trial","volume":"37","author":"S CS da Costa","year":"2019","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ygyno.2013.01.011","article-title":"Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study","volume":"129","author":"R B Singh","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/0360-3016(94)00635-X","article-title":"The adverse effect of treatment prolongation in cervical carcinoma","volume":"32","author":"D G Petereit","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0360-3016(93)90058-4","article-title":"The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study","volume":"25","author":"R M Lanciano","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cncr.27652","article-title":"The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy","volume":"119","author":"S Song","year":"2013","journal-title":"Cancer"},{"issue":"35","key":"ref11","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","article-title":"Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data","volume":"26","author":"Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration","year":"2008","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13063-021-05986-z","article-title":"Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB-IVA cervical cancer: study protocol for a randomized controlled trial","volume":"23","author":"J Li","year":"2022","journal-title":"Trials"},{"issue":"01","key":"ref13","first-page":"42","article-title":"Long-term survival following neoadjuvant chemotherapy and concomitant radiochemotherapy in locally advanced cervical cancer: results of the Oncology Institute \u201cProf. Dr. Ion Chiricuta\u201d experience","volume":"11","author":"A Marita","year":"2018","journal-title":"J Med Life"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/IGC.0b013e3181a130db","article-title":"Intravenous paclitaxel is specifically retained in human gynecologic carcinoma tissues in vivo","volume":"19","author":"H Koshiba","year":"2009","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1038\/bjc.2013.230","article-title":"A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer","volume":"108","author":"M McCormack","year":"2013","journal-title":"Br J Cancer"},{"issue":"16","key":"ref16","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1200\/JCO.2017.75.9985","article-title":"Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage Ib2, IIa, or IIb squamous cervical cancer: a randomized controlled trial","volume":"36","author":"S Gupta","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1776014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:13:11Z","timestamp":1781176391000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/neoadjuvant-chemotherapy-followed-by-interdigitated-brachytherapy-versus-standard-chemoradiation-in-locally-advanced-cervical-cancer\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":16,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2025,12,23]]},"published-print":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0043-1776014","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}